Table 4 Adjuvant therapy

Adj CT only

97

18.5

93

20.0

4

6.6

Doxo–Cyclophos–Paclitaxel

38

7.2

38

8.2

0

0.0

Docetaxel–Cyclophos

26

5.0

24

5.2

2

3.3

Doxo–Cyclophos

11

2.1

11

2.4

0

0.0

Cyclophos–Docetaxel

5

1.0

5

1.1

0

0.0

Doxo–Cyclophos–Docetaxel

3

0.6

3

0.6

0

0.0

Cyclophos–Fluorouracil

3

0.6

2

0.4

1

1.6

Other treatment

11

2.1

10

2.2

1

1.6

Adj CT followed by ET^a

175

33.3

171

36.9

4

6.6

Docetaxel–Cyclophos–Anastrozole

32

6.1

32

6.9

0

0.0

Doxo–Cyclophos–Paclitaxel–Anastrozole

25

4.8

25

5.4

0

0.0

Docetaxel–Cyclophos–Tamoxifen

15

2.9

15

3.2

0

0.0

Doxo–Cyclophos–Paclitaxel–Tamoxifen

10

1.9

10

2.2

0

0.0

Docetaxel–Cyclophos–Letrozole

9

1.7

8

1.7

1

1.6

Doxo–Cyclophos– Paclitaxel–Letrozole

6

1.1

6

1.3

0

0.0

Cyclophos–Docetaxel–Anastrozole

5

1.0

5

1.1

0

0.0

Doxo–Cyclophos–Paclitaxel–Tamoxifen –Anastrozole

4

0.8

4

0.9

0

0.0

Cyclophos–Fluorouracil–Anastrozole

3

0.6

3

0.6

0

0.0

Other treatment

66

12.6

63

13.6

3

4.9

Adj ET only^b

249

47.4

197

42.5

52

85.2

Anastrozole

123

23.4

104

22.4

19

31.1

Tamoxifen

42

8.0

26

5.6

16

26.2

Letrozole

30

5.7

25

5.4

5

8.2

Anastrozole–Letrozole

13

2.5

11

2.4

2

3.3

Letrozole–Anastrozole

7

1.3

5

1.1

2

3.3

Anastrozole–Exemestane

6

1.1

4

0.9

2

3.3

Tamoxifen–Anastrozole

4

0.8

4

0.9

0

0.0

Exemestane

3

0.6

2

0.4

1

1.6

Letrozole–Exemestane

3

0.6

3

0.6

0

0.0

Other treatment

18

3.4

13

2.8

5

8.2

Adj ET followed by CT

4

0.8

3

0.6

1

1.6

Anastrozole–Paclitaxel

1

0.2

0

0.0

1

1.6

Anastrozole–Doxo–Cyclophos–Paclitaxel

1

0.2

1

0.2

0

0.0

Anastrozole–Letrozole–Exemestane –Docetaxel–Cyclophos–Tamoxifen

1

0.2

1

0.2

0

0.0

Letrozole–Cyclophos–Methotrexate –Fluorouracil–Tamoxifen

1

0.2

1

0.2

0

0.0